Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Drug
|
| gptkbp:activeDuring |
Saxagliptin_hydrochloride
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Onglyza
|
| gptkbp:chemicalFormula |
C18H25N3O2S
|
| gptkbp:clinicalTrials |
Phase III
|
| gptkbp:commonName |
2.5 mg to 5 mg once daily
|
| gptkbp:contraindication |
Hypersensitivity to saxagliptin
|
| gptkbp:developer |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:dosageForm |
Tablet
|
| gptkbp:drugInterdiction |
Antidiabetic_agent
|
| gptkbp:gestationPeriod |
Category B
|
| https://www.w3.org/2000/01/rdf-schema#label |
Saxagliptin
|
| gptkbp:interactsWith |
Other antidiabetic agents
|
| gptkbp:nutritionalValue |
Hepatic
|
| gptkbp:releaseYear |
2007
|
| gptkbp:route |
Oral
|
| gptkbp:sells |
Onglyza
|
| gptkbp:sideEffect |
Nausea
Headache Upper respiratory tract infection |
| gptkbp:triggerType |
DPP-4 inhibitor
|
| gptkbp:usedFor |
Type 2 diabetes
|
| gptkbp:waterManagement |
Renal
|